TABLE 5.
Proportion of Prescriptions of the Different Agents as Prophylaxis or Empiric Treatment in the Groups With Underlying Malignancies and HSCT Categorized by Risk
| Antifungal agent | Prophylaxis | Empiric treatment | ||||
|---|---|---|---|---|---|---|
| High risk (n = 449) | Non-high risk + neutropenia (n = 54) | Solid tumors (n = 97) | High risk (n = 81) | Non-high risk + neutropenia (n = 33) | Solid tumors (n = 33) | |
| L-AmB | 175 (39.0%) | 20 (37.0%) | 42 (43.3%) | 46 (56.8%) | 17 (51.5%) | 17 (51.5%) |
| Itraconazole | 187 (41.6%) | 12 (22.2%) | 17 (17.5%) | 1 (1.2%) | 0 | 0 |
| Voriconazole | 26 (5.8%) | 6 (11.1%) | 15 (15.5%) | 7 (8.6%) | 3 (9.0%) | 4 (12.2%) |
| Posaconazole | 36 (8.0%) | 3 (5.6%) | 0 | 7 (8.6%) | 1 (3.0%) | 0 |
| Fluconazole | 5 (1.1%) | 8 (14.8%) | 15 (15.5%) | 4 (4.9%) | 8 (24.2%) | 8 (24.2%) |
| Echinocandins | 18 (4.0%) | 5 (9.2%) | 7 (7.2%) | 12 (14.8%) | 4 (12.1%) | 3 (9.1%) |
| Other | 2 (0.4%) | 0 | 1 (1.0%) | 4 (4.9%) | 0 | 1 (3.0%) |
High risk: post-HSCT patients, relapsed acute lymphoblastic leukemia, acute myeloid leukemia, relapsed acute myeloid leukemia, Hodgkin lymphoma. Non-high risk: acute lymphoblastic leukemia (regardless of chemotherapy protocol), other leukemias, non-Hodgkin lymphomas.